Personalized medicine based on biomarkers is already a reality in some areas of medicine, such as oncology, cardiology, neurology, and infectious diseases. For instance, in oncology, biomarkers can help to identify the genetic mutations or expression patterns of tumors that can predict the response or resistance to certain drugs, such as HER2 for breast cancer, EGFR for lung cancer, or BRAF for melanoma. In cardiology, biomarkers can help to stratify the risk of cardiovascular events and to guide the choice of anticoagulants or antiplatelets, such as troponin for myocardial infarction, or CYP2C19 for clopidogrel. In neurology, biomarkers can help to diagnose and monitor neurodegenerative diseases and to select the best candidates for experimental therapies, such as amyloid-beta and tau for Alzheimer's disease, or alpha-synuclein for Parkinson's disease. In infectious diseases, biomarkers can help to detect and quantify pathogens and to determine the optimal dose and duration of antibiotics, such as PCR for COVID-19, or procalcitonin for bacterial infections.